Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC)
暂无分享,去创建一个
N. Viñolas | R. García-Campelo | A. Gúrpide | U. Jiménez | D. Isla | J. Montalar | J. Fírvida | A. Jaén | P. Regueiro | B. Massutí